Covid 19 Research using Clinical Trials (Home Page)
BMS-986322 PlaceboWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
Correlated MeSH Terms (1)
|
Name (Synonyms) |
Correlation |
D000230 | Adenocarcinoma NIH | 1.00 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
A Study assessing the drug levels and drug effects of variable doses of BMS-986322 in Healthy
Participants compared to a placebo. The study also assesses how BMS-986322 affects the body
with food and its acidity levels.
NCT04175925 Healthy Participants Drug: BMS-986322 Other: BMS-986322 Placebo Drug: famotidine
Primary Outcomes
Measure: Incidence of Death Time: up to 12 months
Measure: Incidence of Adverse Effects (AEs) Time: up to 12 months
Measure: Incidence of Adverse Events leading to discontinuation Time: up to 12 months
Measure: Incidence of Serious Adverse Events (SAEs) Time: up to 12 months
Measure: Vital signs of body temperature Time: up to 12 months
Measure: Vital signs of blood pressure Time: up to 12 months
Measure: Vital signs of respiratory rate Time: up to 12 months
Measure: Number of Participants with abnormal physical examinations Time: up to 12 months
Measure: Number of clinically significant changes in Electrocardiograms (ECGs) Time: up to 12 months
Measure: Number of clinically significant changes in lab assessment of blood serum Time: up to 12 months
Measure: Number of clinically significant changes in lab assessment of urine Time: up to 12 months
Measure: Number of Clinically significant changes in lab assessment of blood Time: up to 12 months
Measure: Maximum concentration (Cmax) of BMS-986322 in Part C Time: up to 12 months
Measure: Time of maximum concentration (Tmax) of BMS-986322 in Part C Time: up to 12 months
Measure: Terminal elimination rate constant (Lambda_z) of BMS-986322 in Part C Time: up to 12 months
Measure: Terminal elimination half-life (T-Half) of BMS-986322 in Part C Time: up to 12 months
Measure: Area under the plasma concentration-time curve extrapolated to infinity [AUC(INF)] of BMS-986322 in Part C Time: up to 12 months
Measure: Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration [AUC(0-T)] of BMS-986322 in Part C Time: up to 12 months
Measure: Apparent oral clearance (CL/F) of BMS-986322 in Part C Time: up to 12 months
Measure: Apparent volume of distrubution at terminal phase (Vz/F) of BMS-986322 in Part C Time: up to 12 months
No related HPO nodes (Using clinical trials)